Quick Answer
Oruka Therapeutics, Inc. reported Operating Income of -$122.05 million for fiscal year 2025.
Oruka Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$122.05M | -38.5% |
| 2024 | -$88.12M | -1107.8% |
| 2023 | -$7.30M | +31.1% |
| 2022 | -$10.60M | +45.2% |
| 2021 | -$19.34M | -98.0% |
| 2020 | -$9.77M | -68.0% |
| 2019 | -$5.81M | +28.4% |
| 2018 | -$8.12M | +56.6% |
| 2017 | -$18.71M | -12.6% |
| 2016 | -$16.61M | -45.0% |
| 2015 | -$11.46M | -18.2% |
| 2014 | -$9.69M | -39.7% |
| 2013 | -$6.94M | -60.7% |
| 2012 | -$4.32M | +41.3% |
| 2011 | -$7.36M | +19.8% |
| 2010 | -$9.18M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$34.10M | -15.8% | -20.0% |
| June 30, 2025 | -$28.43M | -32.3% | -13.3% |
| March 31, 2025 | -$25.09M | -265.5% | +14.8% |
| September 30, 2024 | -$29.45M | -1420.3% | -37.0% |
| June 30, 2024 | -$21.49M | -989.4% | -213.2% |
| March 31, 2024 | -$6.86M | -282.1% | -254.3% |
| September 30, 2023 | -$1.94M | +24.1% | +1.8% |
| June 30, 2023 | -$1.97M | +38.7% | -9.9% |
- Oruka Therapeutics, Inc. showed a decrease of -38.5% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, Oruka Therapeutics, Inc.’s operating income has declined by 1230.3% (from -$9.18 million to -$122.05 million).
- The most recent figure is from Oruka Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: